具備創新特質的公司，除了要擁有追求創新的理念以外，更重要的是不斷地創造公司的價值，而創造價值的方式，可以透過精進技術或是研發新產品來實現，並藉由申請專利保障權益，對製藥產業來說，藥物的專利權尤為重要，因其涉及了公司成長與獲利的關鍵，因此本研究針對製藥產業中的公司核心技術進行相關探討，並且對核心技術中的專利特性進行分析。
本研究針對輝瑞(Pfizer)公司藥物技術進行檢索，主要目的是為了要探討輝瑞(Pfizer)公司藥物技術發展，研究者專注在藥物治療方面的專利，並透過資料庫Derwent Innovation進行搜集，得到了3119筆專利資料，透過主路徑分析法中的關鍵延伸主路徑，找出輝瑞(Pfizer)公司核心發展技術，並使用集群分析法以及單因子變異數分析觀察核心發展技術中的主要技術群，除此之外，採用線性迴歸分析核心技術中專利重要的特性。
根據輝瑞(Pfizer)公司專利的資料，本研究發現了幾個主要的議題，首先，輝瑞(Pfizer)公司核心發展技術為共分為三個階段，第一階段為分子結構變化，接著是分子轉變後變化應用方式，最後則是劑量與方式的調整。研究中所發現的議題還包含了核心發展策略的佈局，核心技術發展中的五個主要技術，分別是青光眼治療、眼藥膏、頭痛治療、真皮填充劑、眼疾酯類化合物，並針對主要技術進行相關重要性的探討發現基礎化合物技術是技術群中最為重要的。最後，亦在核心發展技術中的重要專利所具備的特性，發現擁有基礎分子跨技術的合作與吸收外部知識較多的專利是較關鍵的。

A company with innovative characteristics is more important to continuously create the value of the company. The way to create value for the firm can be achieved by improving technology or developing new products, and applying for patent protection. Therefore, the purpose of the research was to investigate the investigate the development of a firm’s patent and to find out the core technology of the company in the pharmaceutical industry. Another aim was to discover the characteristics of patents in those technology.
The research focus on the patent of Pfizer company, and chose the database from Derwent Innovation and obtained 3119 patents. Then, use Main Path analysis to find out the main development of the company’s technology; and the use for the Edge-betweenness clustering cluster analysis to explore the major aspect of company’s patents. Also, the research also took One-way ANOVA to know the importance of the main technology of Pfizer company. Furthermore, the research also used regression to find out the characteristics of patents.
Finally, as the result showed the research found several major issues. First, Pfizer's core development technology is divided into three stages. The first stage is molecular structure change, followed by is molecular transformation. and the adjustment of dosage and method. The topics found in the research also include the layout of core development strategies, five main technologies in the development of core technologies, namely glaucoma treatment, eye ointment, headache treatment, dermal filler, and eye disease ester compounds. It was found that the basic compound technology is the most important in the technology group. In terms of the characteristics of important patents in core development technologies, it is found that it is more critical to have patents that have more basic molecular cross-technology cooperation and absorb more external knowledge.

Adam, J. D., & Marcu, M. (2004). R&D Sourcing, Joint Ventures and Innovation: A Multiple Indicators Approach. NBER Working Paper No. w10474.
Ahuja, G. (2000) Collaboration Networks, Structural Holes, and Innovation: A Longitudinal Study. Administrative Science Quarterly, 45, 425-455.
Aylward, D. (2006). Innovation lock-in: unlocking research and development path dependency in the Australian wine industry, Strategic Change, 15(7-8), 361-372.
Becker, C. (2014). Organizational routines: a review of the literature. Industrial Corporate Change,13(4),643-677.
Boasson, V., Boasson, E., Macpherson, A., & Shin, H. (2005). Firm Value and Geographic Competitive Advantage: Evidence from the U.S. Pharmaceutical Industry. The Journal of Business, 78(6), 2465–2495.
Caloghirou, Y.; Ioannides, S.; Vonortas, N.S. (2003) Research joint ventures. Economy Survev, 17, 541–570.
Cassiman, B., & Veugelers, R. (2002). R&D Cooperation and Spillovers: Some Empirical Evidence from Belgium. American Economic Review, 92(2), 1169–1184.
Cassman, B. and Veugelers, R. (2002). R&D Cooperation and Spillovers: Some Empirical Evidence from Belgium. American Economic Review, 92, 1169-1184.
Chesbrough, H. (2003). Open innovation: The new imperative for creating and profiting from technology. Harvard Business School: Pinter.
Chesbrough, H., & Rosenbloom, R. S. (2002). The role of the business model in capturing value from innovation: evidence from Xerox Corporation’s technology spin‐off companies. Industrial and Corporate Change, 11(3), 529-555.
Dachs, B. (2009). Innovative activities of multinational enterprises in Austria. Peter Lang, Australia: Pinter
Faria, P. D., Lima, F., & Santos, R. (2010). Cooperation in Innovation Activities: The Importance of Partners. Research Policy, 39(8), 1082–1092.
Freeman, C. (1987). Technology policy and economic performance: Lessons from Japan. London: Pinter.
Fuller, S. (1988). Social epistemology. Indiana University Press.
Griliches, Z., Pakes, A., and Hall, B.H. (1987). The value of patents as indicators of inventive activity. In: Dasgupta, P. and Stoneman, P. (Eds.). Economic Policy and Technological Performance. England: Cambridge University Press, 97–124.
Hagedoorn, J., Link, A.N. and Vonortas, N.S. (2000) Research Partnerships. Research Policy, 29, 567-586.
Hall, B. H., Jaffe, A., & Trajtenberg, M. (2005). Market Value and Patent Citations. Journal of Economics, 36(1), 16–38.
Henderson, Rebecca, Jaffe, Adam B., (2015). Patent citations and the geography of knowledge spillovers: a reassessment: comment. American Economic Review, 95 (1), 461-464.
Hung, Y., Huang, S., Lin, Q. and ‐Tsai, M. (2005), "Critical factors in adopting a knowledge management system for the pharmaceutical industry", Industrial Management & Data Systems, 105 (2), 164-183.
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., Kaldas, M., Gogia, M., Perez-Ruiz, F., Taylor, W., Lioté, F., Choi, H., Singh, J. A., Dalbeth, N., & Kaplan, S., Niyyar, V., (2012). American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis care & research, 64(10), 1431–1446.
Laursen, K. and Salter, A. (2006). Open for Innovation: The Role of Openness in Explaining Innovation Performance among UK Manufacturing Firms. Strategic Management Journal, 27, 131-150.
Lee, J., & K. Park. (2019). The Effect of Personal Creativity on Knowledge Sharing and Innovation Behavior: Focused on Retail Workers. Journal of Distribution Science, 17(10), 93-105
Liu,J.S., Lu,L.Y., Lu,W.M.,& Lin,B.J.(2013).Data envelopment analysis1978–2010:A citation-based literature survey. Omega, 41(1), 3-15.
Lopez, A., Parsons, A. B., Nislow, C., Giaever, G., & Boone, C. (2008). Chemical-Genetic Approaches for Exploring the Mode of Action of Natural Products. Prog Drug Res, 66, 237–239.
Lundvall, B.A. (1992) National Systems of Innovation: Towards a Theory of Innovation and Interactive Learning. Pinter Publishers, London.
Makri, M., & Lane, P. J. (2007). A Search Theoretic Model of Productivity, Science and Innovation. R&D Management, 37(4), 303–317.
Narayana, S.A., Pati, R.K. and Vrat, P. (2012), "Research on management issues in the pharmaceutical industry: a literature review", International Journal of Pharmaceutical and Healthcare Marketing, 6(4), 351-375.
Narula, R. (2002). Innovation Systems and “inertia” in R&D Location: Norwegian Firms and the Role of Systemic Lock-In. Research Policy, 31(5), 795–816.
Nelson, R. (1993). National Innovation Systems: A Comparative Analysis. Oxford University Press, Inc.
Newman, M.E.J., Girvan, M. (2004.) Finding and evaluating community structure in networks. Physical Review E, 69(2), 026113.
Pakes,A., & Schankerman, M . (1984). "An Exploration into the Determinants of Research Intensity," NBER Chapters, in: R&D, Patents, and Productivity, 209-232, National Bureau of Economic Research, Inc.
Rikap, Cecilia. (2018). ‘Innovation as Economic Power in Global Value Chains’. Revue d’Économie Industrielle, 163, 35–75.
Rikap, Cecilia. (2019). Asymmetric Power of the Core: Technological Cooperation and Technological Competition in the Transnational Innovation Networks of Big Pharma. Review of International Political Economy 26(1):1-35
Sushmita A. Narayana, Rupesh Kumar Pati, Prem Vrat. (2012). Research on management issues in the pharmaceutical industry: a literature review. International Journal of Pharmaceutical and Healthcare Marketing.
Tralau-stewart, C. J., Wyatt, C. A., Kleyn, D. E., & Ayad, A. (2009). Drug Discovery: New Models for Industry–Academic Partnerships. Drug Discover Today, 14(1–2), 95–101.
Verspagen, B. (2007). Mapping technological trajectories as patent citation networks :A study on the history of fuel cell research. Advances in Complex Systems, 10(01), 93-115.
野中裕次郎（2006）。創新的本質。台北市：英屬維京群島商高寶國際有限公司台灣分公司。